Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes

Treatment with retatrutide was associated with substantial reductions in atherogenic lipids and inflammatory markers in adults with obesity, with or without type 2 diabetes. In two phase 2 trials, placebo-adjusted improvements were seen across multiple lipoprotein measures and, in the non-diabetic study, in C-reactive protein and interleukin-6.

Journal article — Post hoc analysis of two phase 2 trials. Population: Adults with obesity/overweight, with or without type 2 diabetes, enrolled in two randomised placebo-controlled phase 2 trials. Follow-up: 36–48 weeks. Interventions: Retatrutide once weekly (0.5, 4, 8, 12 mg in Study 1; 1, 4, 8, 12 mg in Study 2).

Retatrutide was associated with significant placebo-adjusted reductions in atherogenic lipoproteins in both trials. Non-HDL cholesterol decreased by up to 21.0% (Study 1) and 26.9% (Study 2); apolipoprotein B fell by 21.4% and 24.2%. Large triglyceride-rich lipoprotein particles decreased by 84.4% and 76.6%, and small low-density lipoprotein particles by 32.6% and 32.3%, in the two studies. In Study 2, high-sensitivity C-reactive protein and interleukin-6 fell by 54.8% and 29.6%, respectively; changes in these inflammatory biomarkers were not significant in Study 1.

This paper provides biomarker-level evidence that retatrutide may improve cardiovascular risk profiles in people with obesity, including those with type 2 diabetes, by lowering atherogenic lipoproteins and, in non-diabetic individuals, inflammatory markers. It does not establish that these biomarker changes reduce cardiovascular events, and the data are hypothesis-generating post hoc analyses from phase 2 trials.

Key findings

Non-HDL cholesterol fell by up to 21.0% in the type 2 diabetes study and by up to 26.9% in the non-diabetic study.
Apolipoprotein B was reduced by 21.4% and 24.2% in the two studies.
Large triglyceride-rich lipoprotein particles decreased by 84.4% (Study 1) and 76.6% (Study 2).
In Study 2, high-sensitivity C-reactive protein fell by 54.8% and interleukin-6 by 29.6%; these changes were not significant in Study 1.
Total low-density lipoprotein particles decreased by 19.7% and 23.5%, and small low-density lipoprotein particles by 32.6% and 32.3%, in the two studies.

Limitations

Post hoc analysis rather than pre-specified primary outcomes.
Phase 2 trials with relatively short follow-up (36–48 weeks).
Inflammatory biomarker changes were not significant in the type 2 diabetes study.
No clinical cardiovascular endpoints were assessed; only biomarkers were measured.

The record

Journal: Diabetes, obesity & metabolism
Published: 2026-08-17
PMID: 42608321 — DOI: 10.1111/dom.71200
Funding: Eli Lilly and Company
Author countries: Australia, UK, USA

Peptide profiles: Retatrutide.

All indexed evidence: Retatrutide trials & papers.